{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:41:56Z","timestamp":1780458116567,"version":"3.54.1"},"reference-count":61,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To measure the impact of national regulatory actions implemented in France in August 2018 and June 2019 to reduce the risk of meningioma associated with the use of cyproterone acetate (CPA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using the French National Healthcare database, we calculated the monthly number of CPA users among cisgender women, men and transgender women in 2010\u20132021, the monthly proportion of users with cerebral imaging screening, and the annual rate of meningioma surgery associated with CPA use. CPA discontinuations and switches were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2018 and 2021, the number of individuals exposed to CPA fell by 85% (55\u2009000 in August 2018 versus 7900 users of high\u2010dose CPA in December 2021), corresponding to two waves of decrease in both use and initiation. This drop was greater among cisgender women (88%) than men (69%) or transgender women (50%). Cerebral imaging screening increased from 11% in June 2018 to 70% in June 2021 for ciswomen (13%\u201351% for men, 9%\u201360% for transwomen). After CPA discontinuation, no massive shift to a single product was observed, but, instead, dispersion towards other hormonal therapies. The overall annual rate of meningioma surgery associated with CPA exposure spectacularly decreased between 2017 and 2021 (\u221293% for ciswomen and \u221286% for men).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In France, high\u2010dose CPA use sharply decreased after the implementation of national regulatory measures without a massive switch to other hormonal therapies. The increase in cerebral imaging screening did not result in an increase in meningioma surgery associated with CPA, but rather a massive drop of over 90%.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.70078","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:25:10Z","timestamp":1736299510000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High\u2010Dose Cyproterone Acetate and Intracranial Meningioma: Impact of the Risk Minimisation Measures Implemented in France in 2018\u20132019"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-4263","authenticated-orcid":false,"given":"No\u00e9mie","family":"Roland","sequence":"first","affiliation":[{"name":"EPI\u2010PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products\u2014ANSM, French National Health Insurance\u2014CNAM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Neumann","sequence":"additional","affiliation":[{"name":"EPI\u2010PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products\u2014ANSM, French National Health Insurance\u2014CNAM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9rang\u00e8re","family":"Baricault","sequence":"additional","affiliation":[{"name":"EPI\u2010PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products\u2014ANSM, French National Health Insurance\u2014CNAM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Dayani","sequence":"additional","affiliation":[{"name":"French National Agency for the Safety of Medicines and Health Products (ANSM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Duranteau","sequence":"additional","affiliation":[{"name":"Department of Medical Gynaecology Bic\u00eatre Hospital, AP\u2010HP, Paris Saclay University  Le Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Fontanel","sequence":"additional","affiliation":[{"name":"Grand Est Regional Health Authority  Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Yoldjian","sequence":"additional","affiliation":[{"name":"French National Agency for the Safety of Medicines and Health Products (ANSM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Froelich","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery Lariboisi\u00e8re University Hospital, AP\u2010HP, Paris\u2010Cit\u00e9 University  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[{"name":"EPI\u2010PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products\u2014ANSM, French National Health Insurance\u2014CNAM)  Saint\u2010Denis France"},{"name":"University of Paris\u2010Saclay, Inserm, Anti\u2010Infective Evasion and Pharmaco\u2010Epidemiology, CESP (Center for Research in Epidemiology and Population Health)  Montigny le Bretonneux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[{"name":"EPI\u2010PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products\u2014ANSM, French National Health Insurance\u2014CNAM)  Saint\u2010Denis France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab200"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34198"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov069"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc071938"},{"key":"e_1_2_11_6_1","article-title":"Does Cyproterone Acetate Promote Multiple Meningiomas?","volume":"16","author":"Froelich S.","year":"2008","journal-title":"Endocrine Abstracts"},{"key":"e_1_2_11_7_1","unstructured":"Cnam \u201cExposition Prolong\u00e9e \u00e0 de Fortes Doses d'ac\u00e9tate de Cyprot\u00e9rone et Risque de M\u00e9ningiome Chez la Femme|L'Assurance Maladie \u201d(2019) https:\/\/assurance\u2010maladie.ameli.fr\/etudes\u2010et\u2010donnees\/2019\u2010acetate\u2010cyproterone\u2010meningiome."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n37"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15423"},{"key":"e_1_2_11_10_1","unstructured":"French health authority (HAS) \u201cCommission de la Transparence\u2014R\u00e9union du 19 D\u00e9cembre 2012\/Transparency Commission 12\/19\/2012 \u201dHaute Autorit\u00e9 de Sant\u00e9 2012 https:\/\/www.has\u2010sante.fr\/jcms\/c_1343639\/fr\/commission\u2010de\u2010la\u2010transparence\u2010reunion\u2010du\u201019\u2010decembre\u20102012."},{"key":"e_1_2_11_11_1","unstructured":"French health authority (HAS) \u201cANDROCUR (Cyprot\u00e9rone (Ac\u00e9tate de)) \u201dHaute Autorit\u00e9 de Sant\u00e9 2016 https:\/\/www.has\u2010sante.fr\/jcms\/c_2655917\/fr\/androcur\u2010cyproterone\u2010acetate\u2010de."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.4331\/wjbc.v13.i3.66"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2011.04031.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00701\u2010015\u20102532\u20103"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3205\/oc000027"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1395839"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010021\u201003696\u20109"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290\u2010023\u201000510\u2010x"},{"key":"e_1_2_11_19_1","unstructured":"ANSM \u201cActualit\u00e9\u2014Androcur (ac\u00e9tate de Cyprot\u00e9rone) et G\u00e9n\u00e9riques: Risque de M\u00e9ningiome Lors d'une Utilisation Prolong\u00e9e \u201dANSM 2018 https:\/\/ansm.sante.fr\/actualites\/androcur\u2010acetate\u2010de\u2010cyproterone\u2010et\u2010generiques\u2010risque\u2010de\u2010meningiome\u2010lors\u2010dune\u2010utilisation\u2010prolongee."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2021.12.002"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21471"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010022\u201031401\u20105"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877\u2010021\u201002568\u20101"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0364"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2599"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010023\u201000584\u20108"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2302134"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231223395"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2024.05.003"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102458\u20109\u201033"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw098"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70022"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi188"},{"key":"e_1_2_11_35_1","unstructured":"JORF \u201cD\u00e9cret n\u00b0 2016\u20131871 du 26 D\u00e9cembre 2016 Relatif au Traitement de Donn\u00e9es \u00e0 Caract\u00e8re Personnel D\u00e9nomm\u00e9 \u00ab\u2009Syst\u00e8me National des Donn\u00e9es de Sant\u00e9\u2009\u00bb \u201d(2016) https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000033702840&categorieLien=id."},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4955"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5552"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010023\u201001314\u20103"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2044"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4556"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007696"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12691"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001077"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2022.02.023"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx763"},{"key":"e_1_2_11_46_1","unstructured":"P.Nguyen L.Hoisnard A.Neumann M.Zureik andA.Weill \u201cAc\u00e9tate de Nom\u00e9gestrol et M\u00e9ningiome \u201d(2021) https:\/\/www.epi\u2010phare.fr\/rapports\u2010detudes\u2010et\u2010publications\/https\u2010www\u2010epi\u2010phare\u2010fr\u2010app\u2010uploads\u20102021\u201004\u2010epi\u2010phare_rapport_acetate_nomegestrol_et_meningiome_20210420\u2010pdf\/."},{"key":"e_1_2_11_47_1","unstructured":"P.Nguyen L.Hoisnard A.Neumann M.Zureik andA.Weill \u201cAc\u00e9tate de Chlomardinone et M\u00e9ningiome \u201d(2021) https:\/\/www.epi\u2010phare.fr\/rapports\u2010detudes\u2010et\u2010publications\/https\u2010www\u2010epi\u2010phare\u2010fr\u2010app\u2010uploads\u20102021\u201004\u2010epi\u2010phare_rapport_acetate_chlormadinone_et_meningiome_20210420\u2010pdf\/."},{"key":"e_1_2_11_48_1","unstructured":"N.Roland A.Neumann L.Hoisnard M.Zureik andA.Weill \u201cUtilisation de Progestatifs et Risque de M\u00e9ningiome Intracr\u00e2nien \u201dEpi\u2010PHARE 2023 https:\/\/www.epi\u2010phare.fr\/rapports\u2010detudes\u2010et\u2010publications\/progestatifs\u2010meningiomes\u2010intracraniens\/."},{"key":"e_1_2_11_49_1","unstructured":"Drugs.com \u201cCyproterone (International Database) \u201dDrugs.Com. 2023 https:\/\/www.drugs.com\/international\/cyproterone.html."},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102021\u2010326138"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab427"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac156"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/26895269.2024.2317395"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gofs.2020.01.001"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0015\u20100282(02)04927\u20100"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gofs.2022.06.001"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010020\u201000481\u2010w"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC\u201019\u20100272"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14329"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2021.05.003"},{"key":"e_1_2_11_61_1","unstructured":"EMA \u201cRestrictions in use of cyproterone due to meningioma risk | European Medicines Agency \u201d(2020) https:\/\/www.ema.europa.eu\/en\/news\/restrictions\u2010use\u2010cyproterone\u2010due\u2010meningioma\u2010risk."},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2010022\u201004124\u20102"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T02:53:01Z","timestamp":1745203981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/pds.70078"],"URL":"https:\/\/doi.org\/10.1002\/pds.70078","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2023-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70078"}}